20/20 BioLabs has secured an exclusive U.S. technology license and access agreement with ROKIT Healthcare to incorporate ROKIT’s chronic kidney disease prediction algorithm into its OneTest for Longevity biomarker risk assessment suite. This collaboration aims to enhance the predictive capabilities of the OneTest for Longevity, which already measures inflammatory biomarkers critical for assessing healthspan and longevity.

The integration of ROKIT’s algorithm is significant for the longevity field, particularly given the clinical evidence linking lower systemic inflammation to improved responses to regenerative therapies. This could lead to better-targeted interventions for chronic kidney disease, a condition affecting over 35 million Americans. The partnership also opens avenues for commercialization in East Asian markets, potentially expanding the reach and impact of longevity-focused diagnostics.

For professionals in the longevity sector, this development underscores the growing intersection of biomarker research and predictive analytics, highlighting the importance of inflammation metrics in therapeutic strategies.

Source: longevity.technology